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The quetiapine active metabolite N-Desalkylquetiapine and the neurotensin NTS1 receptor agonist PD149163 exhibit antidepressant-like effects on operant responding in male rats Major depressive disorder (MDD) is a recurring and debilitating mental disorder with a lifetime prevalence of 14.4% in the United States (Kessler, Petukhova, Sampson, Zaslavsky & Wittchen, 2012) . Clinicians have several types pharmacological treatments available for MDD, which include newer (i.e. selective-serotonin reuptake inhibitors [SSRI] and serotoninnorepinephrine reuptake inhibitors [SNRI] ), older (i.e. tricyclic antidepressants [TCA] and monoamine oxidase inhibitors [MAOI] ), and atypical (e.g., bupropion and vortioxetine) antidepressant medications. However, only about one-half of patients achieve a significant attenuation of symptoms, although not complete symptom remission. Moreover, the delayed onset for an attenuation of symptoms remains a concern for clinically available antidepressant drugs (Fava & Davidson, 1996; Rush et al., 2006; Schulberg, Katon, Simon, & Rush, 1998) .
Novel strategies for antidepressant drugs include glutamatergic antagonists, such as ketamine (Murrough et al., 2013; Zarate et al., 2006) , monotherapy with certain atypical antipsychotic drugs, such as quetiapine (Bortnick et al., 2011; Cutler et al., 2009) , and endogenous substances that may broadly alter monoaminergic neurotransmission, such as the neuropeptide neurotensin.
The atypical antipsychotic drug quetiapine XR (quetiapine fumarate extended release tablets) has been approved by the United States Food and Drug Administration (FDA) as an adjunctive treatment to antidepressants for MDD patients with inadequate response to antidepressant treatment alone. Additionally, quetiapine has shown promise as monotherapy for the treatment of MDD in both clinical and preclinical studies. For example, several clinical studies have shown that once-daily quetiapine XR (50-300 mg/d) produces a rapid reduction in depressive symptoms after one week of treatment and continues to reduce depressive symptoms for six to eight weeks (i.e. the completion of the study) (Bortnick et al., 2011; Cutler et al., 2009; Weisler et al., 2009) . In animals, quetiapine produces antidepressant-like effects in the forced swim test and in behavioral tests following a period of chronic mild stress (Kotagale, Mendhi, Aglawe, Umekar, & Taksande, 2013; Orsetti et al., 2007; Orsetti, Brisco, Rinaldi, Dallorto, & Ghi, 2009 ).
Quetiapine has a diverse pharmacological binding profile with high affinities for histamine (H1) receptors and adrenergic (α1A, α1B, α2C) adrenoceptors, and moderate affinities for serotonin (5-HT1A, 5-HT2A, 5-HT7) and dopamine (D2) receptors (Jensen et al., 2008; Kroeze et al., 2003; Lopez-Munoz & Alamo, 2013) . The active metabolite of quetiapine, Ndesalkylquetiapine, which structurally resembles the tetracyclic antidepressant drugs amoxapine and the TCA desipramine, likely contributes to the antidepressant effects of quetiapine and has high affinities for norepinephrine transporters (NET) and serotonergic (5-HT1A, 5-HT2A, 5-HT2B, 5-HT7), histaminergic (H1), and muscarinic (M1, M3, M5) receptors (Jensen et al., 2008) .
Moreover, N-desalkylquetiapine has reduced immobility in a tail-suspension test without increasing locomotor activity in an open field in mice, and these effects are representative of clinically-effective antidepressant drugs in animal models (Jensen et al., 2008) .
Neurotensin is a widely distributed neuropeptide neurotransmitter that is synthesized and released from dopamine and other neurons and has extensive interactions, primarily via NTS1 receptors, with monoamine, cholinergic, GABAergic, and glutamatergic neurons (Binder, Kinkead, Owens, & Nemeroff, 2001; St-Gelais, Jomphe, & Trudeau, 2006) . These interactions have led to investigations into the potential role of neurotensin in the pathophysiology of central nervous system disorders (St-Gelais et al., 2006) and the evaluation of brain-penetrant neurotensin receptor agonists for the treatment pain (e.g., Buhler Choi, Proudfit, & Gebhart, 2005) , drug dependence (e.g., Fredrickson, Boules, Stennett, & Richelson, 2014) , anxiety (Shilling & Feifel, 2008; Prus, Hillhouse, & LaCrosse, 2014) , and schizophrenia (e.g., Holly, Ebrecht, & Prus, 2011) . Moreover, we previously reported in this journal that the neurotensin NTS1 receptor agonist PD149163 improves memory in Brown Norway rats, suggesting that activation of NTS1 receptors may improve cognitive functioning in schizophrenia (Keiser et al. in press).
A growing literature exists on the potential involvement of neurotensin in depression and the utility of neurotensin receptors agonists for treating depression. Neurotensin NTS1 receptor knockout mice have increased immobility time in the tail suspension test as compared to wildtype controls, which suggests a depression-like phenotype (Fitzpatrick et al., 2012) . Direct injection of neurotensin into the ventral tegmental area was shown to decrease immobility in a forced swim test, an indication of antidepressant-like activity (Cervo, Rossi, Tatarczynska, & Samanin, 1992) . Brain penetrant NTS1 receptor agonists also exhibit behavioral effects in animals models mediated by monoamine neurotransmission. For example, central administration of neurotensin (Luttinger et al., 1982) and systemic administration of the NTS1 receptor agonists PD149163 (Holly et al., 2011) and NT69L (Hertel, Olsen, & Arnt, 2002) reduces conditioned avoidance responding in rats, an effect predictive of clinical antipsychotic efficacy and that is mediated by dopamine D2 receptor antagonism (Wadenberg & Hicks, 1999) . Moreover, systemic administration of the NTS1 receptor agonist NT69L in rats has been shown to increase dopamine concentrations in the medial prefrontal cortex, which may be mediated, in part, by serotonin 5-HT1A receptors (Prus, Huang, Li, Dai, & Meltzer, 2007) .
A further preclinical evaluation of N-Desalkylquetiapine and a NTS1 receptor agonist would aid in evaluating the potential antidepressant effects of these compounds. A reliable behavioral procedure for screening antidepressant drugs in animals is the differentialreinforcement-of-low-rate (DRL) 72 s operant task. In the DRL 72 s procedure, which requires a rat to withhold operant responding for 72 s in order to earn a reinforcer, antidepressant drugs increase reinforcement rates, decrease response rates, and produce a rightward shift in the interresponse time (IRT) distributions (for review, see O'Donnell, Marek, & Seiden, 2005) . For example, imipramine (Tofranil®; TCA), iproniazid (Marsilid®; MAOI), fluoxetine (Prozac®; SSRI), and sertaline (Zoloft®; SSRI) are all antidepressant drugs from different pharmacological classes that produce antidepressant-like effects in the DRL 72 s task (Hillhouse & Porter, 2014; O'Donnell & Seiden, 1982; O'Donnell & Seiden, 1983; Sokolowski & Seiden, 1999) . The DRL 72 s operant procedure offers high predictive validity and is used as tool for screening novel antidepressant drugs. For example, the N-methyl-D-aspartate (NMDA) antagonist ketamine, which produces rapid and sustained antidepressant effects in MDD patients, exhibits an antidepressant-like profile in the DRL 72 s task (Hillhouse & Porter, 2014) .
Thus, the aim of the present study was to assess antidepressant-like effects of the atypical antipsychotic drugs quetiapine, N-Desalkylquetiapine, and the NTS1 receptor agonist PD149163 using the DRL 72 s task. The atypical antipsychotic drug risperidone, which neither exhibits antidepressant effects nor produces an active metabolite with antidepressant effects, the typical antipsychotic drug and D2/3 antagonist raclopride, and the tricyclic antidepressant drug imipramine, which reliably produces an antidepressant-like profile in the DRL 72 s procedure, were assessed for comparison. We hypothesized that quetiapine, N-Desalkylquetiapine, and PD149163 would exhibit antidepressant-like effects in this model, whereas risperidone and raclopride would not produce antidepressant-like effects based on previous literature (for review, see O'Donnell, Marek, & Seiden, 2005) .
Method

Subjects
Twelve adult male Sprague-Dawley rats (Charles River, Portage, MI, USA) weighing between 300 and 350 grams at the start of the experiment were housed individually in plastic cages in a temperature-and humidity-controlled vivarium kept on a 12-h/12-h light/dark cycle (lights on 0700-1900 h). Sprague-Dawley rats were selected because they are commonly used in the DRL 72 s procedure (O'Donnell et al., 2005) . All testing and training sessions occurred during the light cycle, which also was selected based upon other DRL 72 s studies (e.g., Hillhouse & Porter, 2014; O'Donnell et al., 2005; O'Donnell & Seiden, 1982) . After one week of acclimation to the vivarium, daily access to food was restricted in order to maintain the rats at Drug and dose order across rats was counterbalanced using a Latin-square design to minimize impact of drug history effects. Doses and administration routes were based on previous literature (O 'Donnell et al. 2005 ) and preliminary studies in this laboratory.
Differential-reinforcement-of-low-rate 72 s procedure
All rats were first given one session of magazine training in which the house light was on, but the levers were not extended into the chamber. During magazine training, one reinforcer (i.e. food pellet) was delivered noncontingently according to a fixed-time 60 s schedule for 30 min. For the remaining training and test sessions the house light was on and the right lever was extended from the wall. During the next three sessions, rats were trained to lever press under a fixed-ratio 1 reinforcement schedule, in which each lever press resulted in delivery of a reinforcer. Sessions ended after delivery of 30 reinforcers or 60 min, whichever occurred first.
Following the completion of lever press training, all rats started DRL training.
Under the DRL schedule, a response produced a reinforcer only after a specified interresponse interval had elapsed. Lever presses emitted before expiration of the interresponse interval reset the timer and did not produce a reinforcer. The interresponse interval was gradually increased over 15 training sessions. Specifically, DRL training began with an 18 s interresponse interval for 5 sessions, then was increased to 36 s for 10 sessions, and finally increased to 72 s until DRL performance stabilized. DRL performance was considered stable when the number of responses for each individual rat did not vary by more than 10% over 5 out of 6 consecutive sessions. All DRL training and testing sessions were 60 min in length.
Once stable performance under the terminal DRL schedule (i.e. 72 s) was established, test sessions occurred twice weekly (typically Tuesday and Friday) without training sessions between each test session. After the completion of a dose-effect curve for a given drug, the rats received at least three training sessions at the start of the dose-effect curve for the next drug. If DRL performance remained stable in a given rat after completion of testing with the initial drug, then the rat was advanced to testing with another drug.
Data Analysis
The three dependent variables were 1) total number of reinforcers delivered during each test session, 2) total number of responses during each test session, and 3) inter-response times (IRT) for all responses during each test session. All data were expressed as means (+/-standard error of the mean [SEM] ). Response and reinforcer data were analyzed using a one-way repeated measures analysis of variance (ANOVA), with drug dose as the within subjects factor. IRT distributions were obtained by recording responses in nine 12-s bins. To determine if there was a shift in the IRT distribution, a two-way repeated measures ANOVA was used with drug dose as one within subjects factor and interresponse time as the other within subjects factor. Dunnett's multiple comparisons post hoc tests were conducted, as appropriate. Data were analyzed using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA).
Results
Training and baseline performance
Eleven of the 12 rats met the training criterion after a mean of 25.27 (± 3.79 SEM) training sessions. The remaining rat was removed from the study after failing to meet the training criteria within 80 training sessions, which was more than two standard deviations beyond the mean number of sessions to criterion for rats that met the training criteria. A repeated measures ANOVA using "drug vehicle" as the within subjects factor, with the vehicle data for each drug serving as different levels of this factor, did not reveal any significant differences for the number of reinforcers earned or the number of responses emitted over the course of the study (data not shown). 
Quetiapine
Discussion
The present study found that quetiapine, PD149163, risperidone, and imipramine produced antidepressant-like effects using a DRL 72 s task as shown by an increase in reinforcers, a decrease in responses, and a rightward shift in the IRT distributions. This is the first study to report an antidepressant effect generated by an NTS1 receptor agonist. NDesalkylquetiapine produced a partial antidepressant-like effect by decreasing responses and producing a rightward shift in the IRT distributions, and provided a trend toward a significant increase in the number of reinforcers earned (p = 0.08). Conversely, raclopride decreased both the number of reinforcers and responses and flattened the IRT distributions, which is an effect consistent with other D2 receptor antagonists tested in the DRL 72 s task (O'Donnell, Marek, & Seiden, 2005) .
The antidepressant-like effects produced by quetiapine, PD149163, and risperidone are consistent with TCAs (e.g. imipramine and amitriptyline), MAOIs (e.g. tranylcypromine, iproniazid, and isocarboxazid), SSRIs (e.g. fluoxetine and sertraline), and atypical antipsychotics (e.g. clozapine), which also increase reinforcement rate, decrease response rate and shift the IRT distributions to the right (Hillhouse & Porter, 2014; Howard & Pollard, 1984; O'Donnell & Seiden, 1982; O'Donnell & Seiden, 1983; Sokolowski & Seiden, 1999) . In contrast, the typical antipsychotic drugs haloperidol and raclopride have been shown to decrease both reinforcers and responses (Jackson, Koek, & Colpaert, 1995; Seiden, Dahms, & Shaughnessy, 1985;  and in the present study), indicating a lack of antidepressant effects using the DRL 72 s task.
The antidepressant-like effects of quetiapine in the present study supports previous preclinical and clinical reports suggesting that monotherapy with quetiapine produces antidepressant effects. For example, acute administration of quetiapine produces an antidepressant-like effect in mice subjected to the forced swim test by decreasing the time spent immobile (Kotagale et al., 2013) . Additionally, rats treated with chronic administration of quetiapine exhibited an anhedonic reduction in sucrose preference that was shown in nonquetiapine treated rats after acute swim stress and 6 weeks exposure to chronic mild stressors (Orsetti et al., 2007; Orsetti et al., 2009 ). Furthermore, quetiapine XR produces antidepressant effects following acute (one week) and chronic (6 to 8 weeks) treatment in adults and elderly MDD patients (Bortnick et al., 2011; Cutler et al., 2009; Katila et al., 2013; Weisler et al., 2009 ). N-Desalkylquetiapine produced partial antidepressant-like effects in that NDesalkylquetiapine decreased the number of responses and produced a rightward shift in the IRT distributions but did not increase the number of reinforcers earned (although there was a trend towards significant p = .08). N-Desalkylquetiapine is a potent NET inhibitor and partial 5-HT1A agonist and it has a chemical structure similar to the tetracylic antidepressant drug desipramine (Jensen et al., 2008) . Compounds comparable to this profile, such as the NET inhibitor reboxetine and typical antipsychotic drug and tricyclic phenothiazine chlorpromazine, also decreased response rates and shifted IRT distributions to the right without significantly increasing reinforcement rate in this task (Dekeyne, Gobert, Auclair, Girardon, & Millan, 2002; O'Donnell & Seiden, 1983) . N-Desalkylquetiapine has also demonstrated an antidepressant effect in a forced swim task in mice (Jensen et al., 2008) . Moreover, a reduction in depressive symptoms among bipolar disorder patients has been shown to correlate with increased NDesalkylquetiapine/quetiapine plasma ratios (Altamura et al., 2012) . Taken together, the present and earlier findings support the role of an active metabolite contributing to quetiapine's antidepressant effects.
This was the first study to report an antidepressant-like effect by a neurotensin receptor agonist. PD149163 exhibits a high affinity for the neurotensin NTS1 receptor and is devoid of activity at monoaminergic, cholinergic, GABAergic, or glutamatergic neurotransmitter receptors (Petrie et al. 2004) , although PD149163 and other NTS1 receptor agonists exhibit a panoply of effects on other neurotransmitter systems. NTS1 receptors are postsynaptically localized in the ventral tegmental area, basal ganglia, nucleus accumbens, nucleus basalis magnocellularis, and dorsal raphe nuclei (Jolas & Aghajanian, 1997; Binder et al., 2001; St-Galais et al., 2006) . Intracerebroventricular administration of neurotensin has been shown to increase 5-HT turnover in the nucleus accumbens and decrease 5-HT turnover in the ventral tegmental area (Drumheller, Gagne, St-Pierre, & Jolicoeur, 1990) . Activation of postsynaptic NTS1 receptors in the raphe nuclei depolarizes serotonin neurons (Li, Yeh, Tan, Hwang, & Wang, 2001 ) and facilitates serotonin release in the prefrontal cortex (Petkova-Kirova et al., 2008) . NTS1 receptors have close interactions with dopamine, including presynaptic localization of NTS1 receptors on dopamine terminals in the prefrontal cortex and nucleus accumbens. On dopamine terminals, activation of NTS1 receptors inhibit dopamine D2 autoreceptor function, leading to a disinhibition of dopamine efflux (Binder et al., 2001) . Given recent studies describing NTS1 receptor stimulation as a potential treatment for nicotine (Boules et al., 2011) and the ability of these agonist to increase dopamine concentrations in the nucleus accumbens (Sotty et al., 2000; Prus et al., 2007) there is some potential for these compounds to reduce anhedonia in depression by elevating dopamine concentrations in the nucleus accumbens (Treadway & Zald, 2011) .
While previous literature has not shown risperidone to exhibit antidepressant effects in a DRL 72 s procedure (O'Donnell et al., 2005) , risperidone exhibited antidepressant-like effects in the present study. In several clinical case-studies, adjunctive treatment with risperidone has been shown to produce rapid (ranging from one day to two weeks) antidepressant effects and reduce suicidality (O'Connor & Silver, 1998; Ostroff & Nelson, 1999; Stoll & Haura, 2000) . Reeve et al. (2008) extended these findings with a double-blind, placebo-controlled study in which adjunctive risperidone treatment (0.25-2.0 mg/day) reduced both depressive symptoms and suicidality within four days and with effects maintained for the duration of the 8 week study.
Several preclinical studies have shown that adjunctive risperidone treatment with SSRIs and selective serotonin norepinephrine reuptake inhibitors (SNRIs) produces antidepressant-like effects by decreasing the time spent immobile in the forced swim test in mice (Dhir & Kulkarni, 2008) and rats (Iijima, Kurosu, & Chaki, 2010) . In the present study, administration of risperidone produced antidepressant-like effects in the DRL 72 s task, and in previous studies, risperidone has been shown to restore sucrose preference to control levels in rats exposed to seven weeks of chronic mild stress (Marston et al., 2011) and to decrease time spent immobile in pituitary adenylate cyclase-activating polypeptide (PACAP) knockout mice (Hashimoto et al., 2009 ).
With the exception of PD149163, the compounds tested in the present study all function as antagonists for the 5-HT2A receptor (Jensen et al., 2008; Schotte et al., 1996) . Like these compounds, the serotonin 5-HT2A receptor antagonists ketanserin and ritanserin have produced antidepressant-like effects in the DRL 72 s task (Marek, Li, & Seiden, 1989; Marek & Seiden, 1988) . Further, preclinical research has shown that neuroadaptive changes occur for 5-HT2A receptors following behavioral stress procedures and chronic antidepressant treatment. For example, an upregulation of 5-HT2A receptors was shown to occur following isolation rearing in mice and chronic mild stress exposure in rats, but not in animals given repeated administration with citalopram and imipramine, respectively (Günther, Liebscher, Jähkel, & Oehler, 2008; Papp, Klimek, & Willner, 1994) . Additionally, chronic antidepressant treatment has produced a downregulation of 5-HT2A receptors in rat cortex (Papp et al., 1994; Kendall & Nahorski, 1985; Lafaille, Welner, & Suranyi-Cadotte, 1991; Paul et al., 1988; Peroutka & Snyder, 1980; Todd, McManus, & Baker, 1995) . It is possible that antagonism of 5-HT2A receptors produced by the compounds in the present study and in previous studies exhibit an effect pharmacologically similar to effects engendered by downregulation of 5-HT2A receptors, and which may account for the reduced time of onset for antidepressant effects by adjunctive atypical antipsychotic drugs found clinically (Bortnick et al., 2011; Cutler et al., 2009; Katila et al., 2013; Ostroff & Nelson, 1999; Reeve et al., 2008; Weisler et al., 2009) .
Conclusion
This study provided an evaluation of the antidepressant effects of two novel and pharmacologically different compounds, N-Desalkylquetiapine and PD149163. The behavioral findings with N-Desalkylquetiapine add to previous data from preclinical and clinical studies suggesting that this compound engenders antidepressant effects. The present study was the first to evaluate systemic administration of a NTS1 receptor agonist in an antidepressant screening model and revealed that PD149163 engendered, through a very different pharmacological mechanism, effects similar to clinically available antidepressant drugs. Further investigation is needed to determine if neurotensin NTS1 receptor agonists may produce antidepressant effects in other models, as well as to determine if tolerance may occur to these effects after chronic administration. Additional supporting evidence for antidepressant efficacy may establish NTS1 receptor agonism as a novel pharmacologic strategy for antidepressant drug development. relative frequency of responses). Drug doses are indicated in legends. Filled points represent time bin relative frequencies after drug treatment that were significantly different from vehicle as determined by two-way ANOVA followed by a Dunnett's post hoc test. All data were expressed as means ± S.E.M. *p < 0.05 and **p < 0.01 for statistically significant differences compared to vehicle. Figure 2 . Effects of risperidone (n = 11), imipramine (n = 11), and raclopride (n = 11) on DRL 72 s performance in male Sprague-Dawley rats. Left panels (a, d, g) show drug effects on number of reinforcers earned. Center panels (b, e, h) show drug effects on number of responses emitted. Right panels (c, f, i) show drug effects on interresponse time (IRT) distributions. Filled points represent time bin relative frequencies after drug treatment that were significantly different from vehicle as determined by two-way ANOVA followed by a Dunnett's post hoc test. All data were expressed as means ± S.E.M. *p < 0.05 and **p < 0.01 for statistically significant differences compared to vehicle. See figure 1 for other details. 
